Percutaneous coronary interventions in saphenous vein grafts: The more things change, the more they stay the same

EuroIntervention

Volumn 7, Issue 8, 2011, Pages 893-895

  Agostoni, Pierfrancesco ^a   Vermeersch, Paul ^b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b MIDDELHEIM HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CREATINE KINASE MB; TROPONIN;

ANGINA PECTORIS; AORTA GRAFT; ARTERY THROMBOSIS; ATHEROMA; BARE METAL STENT; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY OBSTRUCTION; CORONARY STENT; DISEASE SEVERITY; DRUG ELUTING STENT; EDITORIAL; EMBOLIC PROTECTION DEVICE; FILTER; HEART INFARCTION; HEART MUSCLE INJURY; HEART MUSCLE REVASCULARIZATION; HEART SURGERY; HUMAN; PERCUTANEOUS CORONARY INTERVENTION; RESTENOSIS; SAPHENOUS VEIN GRAFT; SYMPTOM; THROMBOEMBOLISM;

ANGIOPLASTY, BALLOON, CORONARY; DRUG-ELUTING STENTS; EMBOLISM; HUMANS; SAPHENOUS VEIN;

EID: 84855384610     PISSN: 1774024X     EISSN: 19696213     Source Type: Journal    
DOI: 10.4244/EIJV7I8A140     Document Type: Editorial

References (18)

1. Fitzgibbon G, Kafka H, Leach A, Keon WJ, Hooper GD, Burton JR. Coronary bypass graft fate and patient outcome: angiographic follow-up of 5065grafts related to survival and reoperation in 1388 patients during 25 years. J Am Coll Cardiol. 1996;28:616-626. (Pubitemid 26288642)
2. Alexander JH, Hafley G, Harrington RA, Peterson ED, Ferguson TB Jr, Lorenz TJ, Goyal A, Gibson M, Mack MJ, Gennevois D, Califf RM, Kouchoukos NT; PREVENT IV Investigators. Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial. JAMA. 2005;294:2446-2454. (Pubitemid 41627922)
3. Abbate A, Biondi-Zoccai GG, Agostoni P, Lipinski MJ, Vetrovec GW. Recurrent angina after coronary revascularization: a clinical challenge. Eur Heart J. 2007;28:1057-1065. (Pubitemid 47351116)
4. Morrison DA, Sethi G, Sacks J, Henderson WG, Grover F, Sedlis S, Esposito R. Percutaneous coronary intervention versus repeat bypass surgery for patients with medically refractory myocardial ischemia: AWESOME randomised trial and registry experience with post-CABG patients. J Am Coll Cardiol. 2002;40: 1951-1954. (Pubitemid 35425365)
5. Pucelikova T, Mehran R, Kirtane AJ, Kim YH, Fahy M, Weisz G, Lansky AJ, Moussa I, Gray WA, Collins MB, Kodali SK, Stone GW, Moses JW, Leon MB, Dangas G. Short- and long-term outcomes after stent-assisted percutaneous treatment of saphenous vein grafts in the drug-eluting stent era. Am J Cardiol. 2008;101:63-68. (Pubitemid 350297200)
6. Motwani JG, Topol EJ. Aortocoroanry saphenous vein graft disease. Pathogenesis, predisposition, and prevention. Circulation. 1998;97:916-931. (Pubitemid 28113931)
7. Vermeersch P, Agostoni P. Percutaneous treatment of diseased saphenous vein grafts: current state-of-the-art and future directions. Minerva Cardioangiol. 2007;55:637-646. (Pubitemid 350205683)
8. Porto I, Belloni F, Niccoli G, Larosa C, Leone AM, Burzotta F, Trani C, De Maria GL, Hamilton-Craig C, Crea F. Filter no reflow during percutaneous coronary intervention of saphenous vein grafts: incidence, predictors and effect of the type of protection device. EuroIntervention 2011;7:955-961.
9. Porto I, Choudhury RP, Pillay P, Burzotta F, Trani C, Niccoli G, Blackman DJ, Channon KM, Banning AP. Filter no reflow during percutaneous coronary interventions using the Filterwire distal protection device. Int J Cardiol. 2006;109:53-58.
10. Bonello L, De Labriolle A, Lemesle G, Steinberg DH, Roy P, Xue Z, Torguson R, Kaneshige K, Suddath WO, Satler LF, Kent KM, Pichard AD, Lindsay J, Waksman R. Prognostic value of procedure-related myocardial infarction according to the universal definition of myocardial infarction in saphenous vein graft interventions. Am Heart J. 2009;157:894-898.
11. Hong MK, Mehran R, Dangas G, Mintz GS, Lansky AJ, Pichard AD, Kent KM, Satler LF, Stone GW, Leon MB. Creatine kinase-MB enzyme elevation following successful saphenous vein graft intervention is associated with late mortality. Circulation. 1999;100:2400-2405.
12. Vermeersch P, Agostoni P, Verheye S, Van den Heuvel P, Convens C, Bruining N, Van den Branden F, Van Langenhove G. Randomized double-blind comparison of sirolimus-eluting stent versus bare metal stent implantation in diseased saphenous vein grafts: 6-month angiographic, intravascular ultrasound and clinical follow up of the RRISC trial. J Am Coll Cardiol. 2006;48:2423-2431. (Pubitemid 44895571)
13. Brilakis ES, Lichtenwalter C, de Lemos JA, Roesle M, Obel O, Haagen D, Saeed B, Gadiparthi C, Bissett JK, Sachdeva R, Voudris VV, Karyofillis P, Kar B, Rossen J, Fasseas P, Berger P, Banerjee S. A randomized controlled trial of a paclitaxel-eluting stent versus a similar bare-metal stent in saphenous vein graft lesions the SOS (Stenting of Saphenous Vein Grafts) trial. J Am Coll Cardiol. 2009;53:919-928.
14. Mehilli J, Pache J, Abdel-Wahab M, Schulz S, Byrne RA, Tiroch K, Hausleiter J, Seyfarth M, Ott I, Ibrahim T, Fusaro M, Laugwitz KL, Massberg S, Neumann FJ, Richardt G, Schömig A, Kastrati A; (ISAR-CABG) Investigators. Drug-eluting versus bare-metal stents in saphenous vein graft lesions (ISAR-CABG): a randomised controlled superiority trial. Lancet. 2011;378:1071-1078.
15. Jeroudi OM, Abdel-karim AR, Michael TT, Lichtenwalter C, de Lemos JA, Obel O, Addo T, Roesle M, Haagen D, Rangan BV, Raghunathan D, DaSilva M, Saeed B, Bissett JK, Sachdeva R, Voudris VV, Karyofillis P, Kar B, Rossen J, Fasseas P, Berger P, Banerjee S, Brilakis ES. Paclitaxel-eluting stents reduce neointimal hyperplasia compared to bare metal stent in saphenous vein grafts: intravascular ultrasonography analysis of the SOS (Stenting Of Saphenous vein grafts) trial. EuroIntervention. 2011;7:948-954.
16. Agostoni P, Vermeersch P, Semeraro O, Verheye S, Van Langenhove G, Van den Heuvel P, Convens C, Van den Branden F, Bruining N. Intravascular ultrasound assessment of sirolimus-eluting stent versus bare metal stent implantation in diseased saphenous vein grafts (from the RRISC [Reduction of Restenosis In Saphenous vein grafts with Cypher sirolimus-eluting stent] trial). Am J Cardiol. 2007;100:52-58. (Pubitemid 46970699)
17. Vermeersch P, Agostoni P, Verheye S, Van den Heuvel P, Convens C, Van den Branden F, Van Langenhove G. Increased late mortality after sirolimus-eluting stents versus bare metal stents in diseased saphenous vein grafts: results from the randomized DELAYED RRISC trial. J Am Coll Cardiol. 2007;50:261-267. (Pubitemid 47039289)
18. Testa L, Agostoni P, Vermeersch P, Biondi-Zoccai G, Van Gaal W, Bhindi R, Brilakis E, Latini RA, Laudisa ML, Pizzocri S, Lanotte S, Brambilla N, Banning A, Bedogni F. Drug eluting stents versus bare metal stents in the treatment of saphenous vein graft disease: a systematic review and meta-analysis. EuroIntervention. 2010;6:527-536.